Astria Therapeutics (NASDAQ: ATXS) Q3 2025 results release details

Rhea-AI Filing Summary

Astria Therapeutics, Inc. filed a Form 8-K to report that it announced its financial results for the quarter ended September 30, 2025. The company released these results through a press release dated November 12, 2025, which is furnished as Exhibit 99.1 and incorporated by reference. The company also clarifies that the information in Item 2.02 and Exhibit 99.1 is being furnished, not filed, so it is not subject to certain liability provisions under the Securities Exchange Act or automatically incorporated into other SEC filings.

false 0001454789 0001454789 2025-11-12 2025-11-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION 

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 12, 2025

Astria Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-37467		26-3687168
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

22 Boston Wharf Road 10th Floor
Boston, Massachusetts		02210
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (617) 349-1971

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions :

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value per share		ATXS		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company  ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

Item 2.02 Results of Operations and Financial Condition.

On November 12, 2025, Astria Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2025. The full text of the press release issued in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

Exhibit No.		Description
99.1		Press Release issued by the Company on November 12, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		Astria Therapeutics, INC.
Date: November 12, 2025	By:	/s/ Ben Harshbarger
		Ben Harshbarger Chief Legal Officer

FAQ

What did Astria Therapeutics (ATXS) disclose in this Form 8-K?

Astria Therapeutics disclosed that it announced its financial results for the quarter ended September 30, 2025, via a press release furnished as Exhibit 99.1.

How did Astria Therapeutics (ATXS) communicate its Q3 2025 financial results?

The company communicated its quarterly financial results through a press release dated November 12, 2025, which is attached to the Form 8-K as Exhibit 99.1.

Are the Astria Therapeutics (ATXS) financial results in this Form 8-K considered filed with the SEC?

No. The company states that Item 2.02 and Exhibit 99.1 are being furnished, not filed, so they are not subject to Section 18 liability or automatically incorporated into other SEC filings.

What period do the reported Astria Therapeutics (ATXS) results cover?

The reported financial results cover the quarter ended September 30, 2025.

Which exhibit contains the Astria Therapeutics (ATXS) earnings press release?

The earnings press release is included as Exhibit 99.1 to the Form 8-K.

Who signed the Astria Therapeutics (ATXS) Form 8-K?

The Form 8-K was signed on behalf of Astria Therapeutics, Inc. by Ben Harshbarger, the company’s Chief Legal Officer.

On what date did Astria Therapeutics (ATXS) announce its quarterly results?

The company announced its quarterly financial results on November 12, 2025.